Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy

Daris Ferrari, Giuseppe Di Maria, Nicola Fazio, Carla Codecà, Jessica Fiore, Andrea Luciani, Sabina Oldani, Marco Maggioni, Paolo Foa

Research output: Contribution to journalArticle

Abstract

Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed. Systemic chemotherapy is seldom effective in inducing objective response and prolonging survival. We report a case of complete pathological remission of hepatocellular carcinoma after three cycles of systemic chemotherapy. A 64-year-old woman presented with histologically documented hepatocellular carcinoma without associated liver disease, relapsed after earlier locoregional therapy. Surgery was not performed as thoracic computerized tomography (CT) demonstrated pulmonary bilateral nodules. The patient was treated with chemotherapy consisting of three cycles of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF regimen); stable lung disease and a good partial response in the liver were obtained as documented by CT scan. Hepatic segmentectomy was therefore performed and the histologic examination revealed necrosis without evidence of residual disease. Two more cycles of adjuvant chemotherapy were infused after surgery. At 1-year follow-up the patient is alive and free of disease according to a positron emission tomography/CT scan. It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease.

Original languageEnglish
Pages (from-to)837-840
Number of pages4
JournalAnti-Cancer Drugs
Volume19
Issue number8
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Combination Drug Therapy
Hepatocellular Carcinoma
Tomography
Drug Therapy
Liver Diseases
Epirubicin
Segmental Mastectomy
Liver
Adjuvant Chemotherapy
Secondary Prevention
Fluorouracil
Positron-Emission Tomography
Cisplatin
Lung Diseases
Necrosis
Thorax
Lung
Survival
FPEPIR regimen
Therapeutics

Keywords

  • ECF regimen
  • Hepatocellular carcinoma
  • Systemic chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. / Ferrari, Daris; Di Maria, Giuseppe; Fazio, Nicola; Codecà, Carla; Fiore, Jessica; Luciani, Andrea; Oldani, Sabina; Maggioni, Marco; Foa, Paolo.

In: Anti-Cancer Drugs, Vol. 19, No. 8, 09.2008, p. 837-840.

Research output: Contribution to journalArticle

Ferrari, Daris ; Di Maria, Giuseppe ; Fazio, Nicola ; Codecà, Carla ; Fiore, Jessica ; Luciani, Andrea ; Oldani, Sabina ; Maggioni, Marco ; Foa, Paolo. / Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. In: Anti-Cancer Drugs. 2008 ; Vol. 19, No. 8. pp. 837-840.
@article{3ba67a4c81b24871a6aa5636f36a30de,
title = "Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy",
abstract = "Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed. Systemic chemotherapy is seldom effective in inducing objective response and prolonging survival. We report a case of complete pathological remission of hepatocellular carcinoma after three cycles of systemic chemotherapy. A 64-year-old woman presented with histologically documented hepatocellular carcinoma without associated liver disease, relapsed after earlier locoregional therapy. Surgery was not performed as thoracic computerized tomography (CT) demonstrated pulmonary bilateral nodules. The patient was treated with chemotherapy consisting of three cycles of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF regimen); stable lung disease and a good partial response in the liver were obtained as documented by CT scan. Hepatic segmentectomy was therefore performed and the histologic examination revealed necrosis without evidence of residual disease. Two more cycles of adjuvant chemotherapy were infused after surgery. At 1-year follow-up the patient is alive and free of disease according to a positron emission tomography/CT scan. It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease.",
keywords = "ECF regimen, Hepatocellular carcinoma, Systemic chemotherapy",
author = "Daris Ferrari and {Di Maria}, Giuseppe and Nicola Fazio and Carla Codec{\`a} and Jessica Fiore and Andrea Luciani and Sabina Oldani and Marco Maggioni and Paolo Foa",
year = "2008",
month = "9",
doi = "10.1097/CAD.0b013e32830c2380",
language = "English",
volume = "19",
pages = "837--840",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy

AU - Ferrari, Daris

AU - Di Maria, Giuseppe

AU - Fazio, Nicola

AU - Codecà, Carla

AU - Fiore, Jessica

AU - Luciani, Andrea

AU - Oldani, Sabina

AU - Maggioni, Marco

AU - Foa, Paolo

PY - 2008/9

Y1 - 2008/9

N2 - Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed. Systemic chemotherapy is seldom effective in inducing objective response and prolonging survival. We report a case of complete pathological remission of hepatocellular carcinoma after three cycles of systemic chemotherapy. A 64-year-old woman presented with histologically documented hepatocellular carcinoma without associated liver disease, relapsed after earlier locoregional therapy. Surgery was not performed as thoracic computerized tomography (CT) demonstrated pulmonary bilateral nodules. The patient was treated with chemotherapy consisting of three cycles of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF regimen); stable lung disease and a good partial response in the liver were obtained as documented by CT scan. Hepatic segmentectomy was therefore performed and the histologic examination revealed necrosis without evidence of residual disease. Two more cycles of adjuvant chemotherapy were infused after surgery. At 1-year follow-up the patient is alive and free of disease according to a positron emission tomography/CT scan. It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease.

AB - Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed. Systemic chemotherapy is seldom effective in inducing objective response and prolonging survival. We report a case of complete pathological remission of hepatocellular carcinoma after three cycles of systemic chemotherapy. A 64-year-old woman presented with histologically documented hepatocellular carcinoma without associated liver disease, relapsed after earlier locoregional therapy. Surgery was not performed as thoracic computerized tomography (CT) demonstrated pulmonary bilateral nodules. The patient was treated with chemotherapy consisting of three cycles of epirubicin, cisplatin, and infusional 5-fluorouracil (ECF regimen); stable lung disease and a good partial response in the liver were obtained as documented by CT scan. Hepatic segmentectomy was therefore performed and the histologic examination revealed necrosis without evidence of residual disease. Two more cycles of adjuvant chemotherapy were infused after surgery. At 1-year follow-up the patient is alive and free of disease according to a positron emission tomography/CT scan. It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease.

KW - ECF regimen

KW - Hepatocellular carcinoma

KW - Systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=53749103405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749103405&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32830c2380

DO - 10.1097/CAD.0b013e32830c2380

M3 - Article

C2 - 18690097

AN - SCOPUS:53749103405

VL - 19

SP - 837

EP - 840

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -